Alopecia Areata as an Immune-Related Adverse Event Associated with Response to Immune Checkpoint Inhibitors

The study analyzed the effectiveness of brodalumab versus ustekinumab in treating psoriasis using absolute PASI scores. Data from the Phase III AMAGINE-2 and -3 trials showed that over 52 weeks, a higher proportion of patients achieved lower absolute PASI scores with brodalumab compared to ustekinumab. The probability of achieving a response state was significantly greater with brodalumab (hazard ratio: 1.96), and at Week 52, 81% of patients on brodalumab were in response compared to 60% on ustekinumab. Additionally, the mean time in response was longer for brodalumab (215 days) than for ustekinumab (145 days), indicating brodalumab's superior efficacy in maintaining a response.